Arbutus Biopharma Corporation
ABUSArbutus Biopharma is a clinical-stage biopharmaceutical company dedicated to developing a functional cure for chronic hepatitis B (cHBV).
Earnings
Next report
Nov 16, 2026 (in a month)Financials
Q2 2026Valuation & ratios
Segments
Competitors
By market cap
By revenue growth
By net margin
Profile
Arbutus Biopharma is a clinical-stage biopharmaceutical company dedicated to developing a functional cure for chronic hepatitis B (cHBV). The company leverages its proprietary lipid nanoparticle (LNP) delivery technology and a pipeline of RNA interference (RNAi) and oral PD-L1 inhibitor therapeutics to suppress viral replication and restore the patient's immune response. Arbutus also actively monetizes and defends its intellectual property portfolio related to LNP technology through licensing and litigation.
Arbutus is a specialized player in the cHBV space with a leading RNAi candidate and a foundational, highly-litigated LNP delivery platform.
FAQ
- What is Arbutus Biopharma Corporation's market cap?
- Arbutus Biopharma Corporation (ABUS) has a market capitalization of $903.4M and trades on NASDAQ.
- What is Arbutus Biopharma Corporation's revenue and profitability?
- Arbutus Biopharma Corporation generated $181.7M in trailing twelve-month revenue with net income of $153.1M, representing a net margin of 84.2%. The latest reported period is Q2 2026.
- Who are Arbutus Biopharma Corporation's competitors?
- Arbutus Biopharma Corporation's key competitors include Arrowhead Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Gilead Sciences, Inc., and others. These companies compete in similar markets and product categories.
- Who does Arbutus Biopharma Corporation partner with?
- Arbutus Biopharma Corporation's notable partners include Genevant Sciences GmbH, Barinthus Biotherapeutics plc, Moderna, Inc., and others.
- Where is Arbutus Biopharma Corporation headquartered?
- Arbutus Biopharma Corporation is headquartered in United States of America and employs approximately 73 people. It has been publicly traded since 2007.
